HIV Vaccine Blueprint Calls For Industry R&D Model, Clinical Trials Network
This article was originally published in The Pink Sheet Daily
Governments also must provide push-and-pull incentives for vaccine development, the International AIDS Vaccine Initiative says.
You may also be interested in...
Minority recruitment into HIV vaccine trials could be a serious issue based on attitudes and knowledge revealed in a recent survey, one of the survey authors suggests.
Creating incentives for the private sector to enter into HIV/AIDS vaccine research and development efforts is one suggestion from the International AIDS Vaccine Initiative in a new report released at the 15th International AIDS Conference in Bangkok.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.